-$0.32 EPS Expected for REDHILL BIOPHAR/S (NASDAQ:RDHL) This Quarter

Wall Street brokerages expect REDHILL BIOPHAR/S (NASDAQ:RDHL) to report earnings per share (EPS) of ($0.32) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for REDHILL BIOPHAR/S’s earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.30). REDHILL BIOPHAR/S posted earnings of ($0.34) per share in the same quarter last year, which suggests a positive year over year growth rate of 5.9%. The business is scheduled to issue its next quarterly earnings report on Tuesday, February 25th.

On average, analysts expect that REDHILL BIOPHAR/S will report full-year earnings of ($1.38) per share for the current fiscal year, with EPS estimates ranging from ($1.60) to ($1.10). For the next financial year, analysts forecast that the firm will post earnings of ($0.80) per share, with EPS estimates ranging from ($1.10) to ($0.50). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow REDHILL BIOPHAR/S.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of REDHILL BIOPHAR/S from a “buy” rating to a “hold” rating in a report on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of REDHILL BIOPHAR/S in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $18.00.

A number of large investors have recently bought and sold shares of RDHL. Ibex Investors LLC increased its stake in REDHILL BIOPHAR/S by 91.3% in the 2nd quarter. Ibex Investors LLC now owns 1,867,000 shares of the biotechnology company’s stock worth $12,136,000 after acquiring an additional 891,072 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of REDHILL BIOPHAR/S in the 2nd quarter valued at about $384,000. Boston Partners purchased a new stake in shares of REDHILL BIOPHAR/S in the 3rd quarter valued at about $190,000. CLARET ASSET MANAGEMENT Corp boosted its position in shares of REDHILL BIOPHAR/S by 22.1% during the 3rd quarter. CLARET ASSET MANAGEMENT Corp now owns 75,102 shares of the biotechnology company’s stock valued at $529,000 after acquiring an additional 13,600 shares during the last quarter. Finally, Disciplined Growth Investors Inc. MN boosted its position in shares of REDHILL BIOPHAR/S by 0.4% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,145,014 shares of the biotechnology company’s stock valued at $8,061,000 after acquiring an additional 4,550 shares during the last quarter. 37.00% of the stock is owned by institutional investors.

Shares of RDHL stock traded down $0.24 during trading hours on Wednesday, reaching $6.20. The stock had a trading volume of 183,159 shares, compared to its average volume of 123,554. The stock’s fifty day simple moving average is $6.49 and its 200 day simple moving average is $6.98. The company has a current ratio of 2.22, a quick ratio of 2.08 and a debt-to-equity ratio of 0.13. REDHILL BIOPHAR/S has a 12 month low of $5.13 and a 12 month high of $9.20. The firm has a market capitalization of $136.00 million, a PE ratio of -3.65 and a beta of 1.33.

About REDHILL BIOPHAR/S

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.